NB
ABOS icon

NBT Bank’s Acumen Pharmaceuticals ABOS Stock Holding History

NBT Bank’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$472 – 1063
2026
Q1 		$472 Buy
200
+198
+9,900% +$505 ﹤0.01% 1006
2025
Q4 		$422 Hold
2
– – ﹤0.01% 799
2025
Q3 		$342 Sell
2
-198
-99% -$274 ﹤0.01% 795
2025
Q2 		$232 Buy
+200
New +$215 ﹤0.01% 780

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

NBT Bank's ABOS Position: Q2 2026 in Review

NBT Bank sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 200 shares — an estimated $472 sold.

NBT Bank first reported a position in ABOS in Q2 2025 and held it in 4 quarters. The position peaked at $472 in Q1 2026. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • NBT Bank reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • NBT Bank sold 200 Acumen Pharmaceuticals shares in Q2 2026, an estimated $472.
  • NBT Bank first reported a position in Acumen Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • NBT Bank's Acumen Pharmaceuticals position peaked at $472 in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on NBT Bank's 13F filing for Q2 2026, filed 29 Jul 2026.